Oncocentro | Vina Del Mar, Chile

Research site

(Unclaimed)

Location

Avenida La Marina #1702, Vina Del Mar, Valparaiso, Chile

Site insights

Top conditions

Top treatments

Pembrolizumab

MK-7902

Enzalutamide

Deucravacitinib

Cemiplimab

Lenvatinib

Fianlimab

Androgen

MK-3475-826

MK-7339

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 14 total trials

Locations recently updated

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome (POETYK SjS-1)

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling

Sjögren's Syndrome

Other: Placebo

Drug: Deucravacitinib

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN281...

Enrolling

Melanoma

Drug: Cemiplimab

Drug: Placebo

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalut...

Active, not recruiting

Metastatic Hormone-Sensitive Prostate Cancer

Drug: Androgen Deprivation Therapy (ADT)

Other: Placebo

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-...

Active, not recruiting

Melanoma

Other: Placebo

Biological: Pembrolizumab

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have...

Active, not recruiting

Renal Cell Carcinoma

Drug: Placebo

Biological: Pembrolizumab

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembro...

Active, not recruiting

Malignant Melanoma

Drug: Lenvatinib

Drug: Placebo for lenvatinib

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvat...

Active, not recruiting

Nonsquamous Non-small Cell Lung Cancer

Drug: Cisplatin

Drug: Placebo matching lenvatinib

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurre...

Active, not recruiting

Uterine Cervical Neoplasms

Drug: Cisplatin

Biological: Pembrolizumab

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenanc...

Active, not recruiting

Peritoneal Neoplasms

Fallopian Tube Cancer

Drug: Docetaxel

Drug: Placebo for olaparib

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after in...

Active, not recruiting

Triple Negative Breast Neoplasms

Biological: Pembrolizumab

Drug: Gemcitabine

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, wit...

Active, not recruiting

Endometrial Neoplasms

Drug: Placebo for pembrolizumab

Drug: Cisplatin

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men...

Active, not recruiting

Prostatic Neoplasms

Drug: Placebo

Biological: Pembrolizumab

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by eit...

Active, not recruiting

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Drug: Cisplatin

Biological: Pembrolizumab

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms